Abstract:Shuo Li, 1, 2 Tingyu Zhang, 1, 2 Xin Sun, 1, 2 Xiaoke Li 1, 2 1 Department of Gastroenterology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, People's Republic of China; 2 Institute of Liver Diseases, Beijing University of Chinese Medicine, Beijing, People's Republic of China Correspondence: Xiaoke Li, Beijing University of Chinese Medicine, Haiyuncang 5, Dongcheng District, Beijing, People's Republic of China, Tel +86 010-84015503, Email Purpose: Immunogenic cell death (ICD) is a type of regulated cell death that modifies the immune response by releasing DAMPs or danger signals. Herein, we aimed to develop an ICD-related predictive model for patients with hepatocellular carcinoma (HCC) and investigate its applicability for predicting prognostic outcomes and immunotherapeutic responses. Methods: Differentially expressed genes of ICD were identified in the HCC and normal liver samples. A prognostic risk model and a nomogram containing clinicopathological features were created. To validate the effectiveness of the model, an external dataset was used. Clinical characteristics, prognosis, tumor mutation burden, immune microenvironments, biological function and chemotherapeutic drug sensitivity were evaluated for different genetic subtypes and risk groups. Results: A total of 35 ICD-related genes (ICDRGs) were identified between HCC and normal samples, 11 of which were significantly associated with overall survival (OS) in HCC patients. Four different genetic subtypes were formed and eight ICDRGs were selected to develop a risk prognostic model. The risk scores were shown to be an independent prognostic factor for HCC and positively correlated with pathological severity. Patients in the high-risk group had a higher frequency of TP53 mutations, increased expression of immune checkpoints and human leukocyte antigen genes. The inhibitory concentrations of chemotherapeutic drugs differed in different populations. Conclusion: In this study, we developed an ICDRG risk model and demonstrated its applicability in predicting survival outcomes, immune and chemotherapeutic responses in HCC patients. ICDRGs are expected to be used as novel biomarkers in the medical decision-making of HCC. Keywords: immunogenic cell death-related genes, hepatocellular carcinoma, prognosis, immune microenvironments, drug sensitivity The prevalence of liver cancer is rising globally, and it continues to be a problem for global health. 1,2 By 2025, liver cancer is expected to impact over one million people. 3 Hepatocellular carcinoma (HCC) is the most common type of liver cancer, accounting for 90% of cases. 4 The development of HCC is a complex process involving ongoing inflammatory damage, regeneration, and necrosis of hepatocytes. The survival of cancer cells was facilitated by anomalies in molecular signaling and gene expression, which was the core reason for the development of cancer. 5 In recent years, immunotherapy based on the modulation of the tumor immune microenvironments has become a new therapy for HCC patients, but remission rates were unsatisfactory. HCC was a typical immunogenic cancer that usually develops in a setting of ongoing inflammation. 6 HCC developed while the immune system was in a "cool" state, shielding it from cytolytic attack by lymphocytes entering the tumor. The purpose of immunotherapy was to transform the "cold" state of tumor immunity into a "hot" state and thus restructure the tumor immune environment to enhance the anti-tumor immune responses. 7 The main difficulty with immunotherapy for HCC was that the immune system was prevented from exerting its typical anti-tumor effects by the tumor immune escape mechanisms, the tumor suppressive immunological microenvironments and the low immunogenicity of tumor cells. Exploring the precise biomarkers for immunotherapy will be especially crucial given the advancements in immunotherapy. Immunogenic cell death (ICD) was thought to be one of the most effective methods for completely eliminating tumor cells due to its ability to stimulate immune responses and create long-lasting immunological memory. 8–10 Increasing evidence demonstrated that some chemotherapy drugs not only directly killed tumor cells, but also had the capacity to induce ICD. 11–14 ICD was a type of cell death caused by releasing tumor associated antigen (TAA) and tumor specific antigen (TSA) in order to activate the immune response of the immune system. 15 The immunogenic characteristics of ICD were mainly mediated by damage-associated molecular patterns (DAMPs), which include surface-exposed calreticulin, -Abstract Truncated-

Comprehensive analysis of immunogenic cell death associated genes expression, tumor microenvironment, and prognosis in hepatocellular carcinoma

A Novel Immunogenic Cell Death-Related Genes Signature for Predicting Prognosis, Immune Landscape and Immunotherapy Effect in Hepatocellular Carcinoma.

Interleukin-2 Inducible T-cell Kinase: a Potential Prognostic Biomarker and Tumor Microenvironment Remodeling Indicator for Hepatocellular Carcinoma.

An immunogenic cell death-associated gene signature predicts prognosis in hepatocellular carcinoma

In-depth Characterization of the Biomarkers Based on Tumor-Infiltrated Immune Cells Reveals Implications for Diagnosis and Prognosis in Hepatocellular Carcinoma.

A Novel Prognostic Model Based on Immunogenic Cell Death-Related Genes for Improved Risk Stratification in Hepatocellular Carcinoma Patients.

Integration of Single-Cell RNA Sequencing and Bulk RNA Sequencing to Identify an Immunogenic Cell Death-Related 5-Gene Prognostic Signature in Hepatocellular Carcinoma

Prognostic Value and Immune Landscapes of Immunogenic Cell Death-Related Lncrnas in Hepatocellular Carcinoma.

Construction of an Immunogenic Cell Death-Related Gene Signature and Genetic Subtypes for Predicting Prognosis, Immune Microenvironments, and Drug Sensitivity in Hepatocellular Carcinoma

Identification of Prognostic Genes in the Tumor Microenvironment of Hepatocellular Carcinoma

A Novel Prognostic Signature Based on Immunogenic Cell Death Score Predicts Outcomes and Response to Transcatheter Arterial Chemoembolization and Immunotherapy in Hepatocellular Carcinoma

An Immunogenic Cell Death-Related Classification Predicts Prognosis and Response to Immunotherapy in Hepatocellular carcinoma

Exploring the prognostic significance of immunogenic cell death‐related genes as risk biomarkers in cervical cancer

Identification and Analysis of Immune-Related Gene Signature in Hepatocellular Carcinoma

Prediction of clinical prognosis and drug sensitivity in hepatocellular carcinoma through the combination of multiple cell death pathways

Comprehensive analysis of diverse programmed cell death patterns in the prognosis, tumor microenvironment and drug sensitivity in hepatocellular carcinoma

Risk Predictive Model Based on Three DDR-Related Genes for Predicting Prognosis, Therapeutic Sensitivity, and Tumor Microenvironment in Hepatocellular Carcinoma

A novel immune-related genes prognosis biomarker for hepatocellular carcinoma

Identification, Verification and Pathway Enrichment Analysis of Prognosis-Related Immune Genes in Patients With Hepatocellular Carcinoma

Identification and Validation of Novel Immunogenic Cell Death- and DNA Damage Response-Related Molecular Patterns Correlated with Immune Status and Prognosis in Hepatocellular Carcinoma

Establishment and Validation of a Novel CD8+ T Cell-Associated Prognostic Signature for Predicting Clinical Outcomes and Immunotherapy Response in Hepatocellular Carcinoma Via Integrating Single-Cell RNA-seq and Bulk RNA-seq.